TL;DR:
- FUSE-AI introduces “Prostate.Carcinoma.ai” AI software for radiology with EU Medical Device Regulation (MDR) certification.
- The software automates prostate gland segmentation and detects pathological changes, saving 30% of radiologists’ time.
- Radiological clinics and practices are showing strong interest in the AI algorithm.
- Integration into existing clinical software preserves user-friendliness.
- The software has undergone rigorous testing in clinical trials.
- The global medical image analysis software market is projected to reach $4.545 billion by 2023.
- FUSE-AI presents its product at Arab Health in Dubai, emphasizing a reseller distribution strategy.
- FUSE-AI’s integration approach with existing radiology software is a key sales argument.
- “Prostate.Carcinoma.ai” is the flagship product in a suite of AI-powered diagnostic assistance software.
Main AI News:
In a groundbreaking development for the field of radiology, FUSE-AI GmbH has officially introduced its cutting-edge AI software, “Prostate.Carcinoma.ai,” following the attainment of the EU Medical Device Regulation (MDR) 2017/745 IIa certification. Effective from January 2024, FUSE-AI is authorized to market its software as a certified medical product.
“Prostate.Carcinoma.ai” represents a significant advancement, offering invaluable support to radiologists by automating the segmentation of the prostate gland in MRI scans and independently detecting pathological changes. This innovation is estimated to result in a substantial 30% reduction in the time required for each patient’s examination. The efficiency gains translate into considerable financial advantages for radiological clinics and practices, igniting considerable interest in the widespread adoption of this AI algorithm. Importantly, the software integrates seamlessly into existing clinical software systems, ensuring user-friendliness while preserving radiologists’ familiarity with their work environment. Furthermore, the product has undergone rigorous testing in evidence-based clinical trials by fellow radiologists.
Matthias Steffen, Founder and CEO of FUSE-AI, expressed his enthusiasm, saying, “This AI software is a testament to the collaborative efforts of scientists, AI developers, and radiologists. Achieving certification marks a pivotal milestone, converting initial agreements into legally binding contracts and enabling us to fully harness the software’s capabilities in clinical settings. This achievement significantly mitigates investment risks for our company.”
This favorable development for “Prostate.Carcinoma.ai” aligns perfectly with forecasts projecting the global market for medical image analysis software to achieve a staggering valuation of $4.545 billion by 2023, demonstrating a robust Compound Annual Growth Rate (CAGR) of 9.9 percent.
At the prestigious Arab Health event in Dubai, a prominent healthcare exhibition in the Middle East, FUSE-AI is set to unveil its flagship product, “Prostate.Carcinoma.ai,” and outline its reseller distribution strategy from January 29 to February 1, 2024.
Notably, FUSE-AI’s distribution strategy stands out as a key selling point. The company seamlessly integrates its AI algorithm into established radiology software. This approach capitalizes on existing contracts between software manufacturers and providers (PACS) and healthcare clinics and practices, turning them into resellers. This strategic move empowers FUSE-AI to leverage the multiplier effect, efficiently reaching a vast network of clinics simultaneously.
“Prostate.Carcinoma.ai” serves as the flagship offering in a suite of AI-powered diagnostic assistance software solutions designed for various medical indications. This positions FUSE-AI for a robust global clinical presence, solidifying its software as an indispensable tool in the field of medical diagnostics.
Conclusion:
FUSE-AI’s EU-certified AI software “Prostate.Carcinoma.ai” offers substantial time savings for radiologists and has generated significant interest in the market. With a promising global medical image analysis software market forecast, FUSE-AI’s strategic integration approach positions them for substantial growth and a solid presence in the field of medical diagnostics.
